Phathom Pharmaceuticals, Inc. Income after Tax

Income after Tax of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Income after Tax growth rates and interactive chart.


Highlights and Quick Summary

  • Income after Tax for the quarter ending June 29, 2021 was $-36.6 Million (a 4.9% increase compared to previous quarter)
  • Year-over-year quarterly Income after Tax increased by 7.17%
  • Annual Income after Tax for 2020 was $-129 Million (a -49.41% decrease from previous year)
  • Annual Income after Tax for 2019 was $-255 Million (a 19708.31% increase from previous year)
  • Twelve month Income after Tax ending June 29, 2021 was $-159 Million (a 10.75% increase compared to previous quarter)
  • Twelve month trailing Income after Tax decreased by -8.15% year-over-year
Trailing Income after Tax for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-159 Million $-144 Million $-129 Million $-173 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Income after Tax of Phathom Pharmaceuticals, Inc.

Most recent Income after Taxof PHAT including historical data for past 10 years.

Interactive Chart of Income after Tax of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Income after Tax for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-36.55 $-34.84
2020 $-53.72 $-34.11 $-21.1 $-20.14 $-129.07
2019 $-98.01 $-68.11 $-87.76 $-1.25 $-255.13
2018 $-0.29 $-1.29

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.